Internal Reference Number: FOI_9273
Date Request Received: 06/03/2026 00:00:00
Date Request Replied To: 24/03/2026 00:00:00
This response was sent via: By Email
Request Summary: Endometrial Cancer
Request Category: Researcher
| Question Number 1: Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments? | |
| Answer To Question 1: Yes | |
| Question Number 2: How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: • Dostarlimab (Jemperli) • Dostarlimab (Jemperli) + Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Lenvatinib + Pembrolizumab (Keytruda + Lenvima) • Pembrolizumab monotherapy (Keytruda) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Durvalumab with Platinum-based Chemotherapy • Pembrolizumab with Platinum-based Chemotherapy • Any other SACT • If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for Endometrial Cancer | |
| Answer To Question 2: Please see results below: • Dostarlimab (Jemperli) 0 • Dostarlimab (Jemperli) + Chemotherapy <=5 • Hormone therapy (Progesterone or Letrozole) information not available • Lenvatinib + Pembrolizumab (Keytruda + Lenvima) <=5 • Pembrolizumab monotherapy (Keytruda) 0 • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) <=5 • Durvalumab with Platinum-based Chemotherapy 0 • Pembrolizumab with Platinum-based Chemotherapy <=5 • Any other SACT 0 | |
| Question Number 3: In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy? | |
| Answer To Question 3: <=5 | |
| Question Number 4: In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: • Dostarlimab (Jemperli) + Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Durvalumab with Platinum-based Chemotherapy • Pembrolizumab with Platinum-based Chemotherapy • Any other SACT • If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for first line Endometrial cancer | |
| Answer To Question 4: Dostarlimab (Jemperli) + Chemotherapy 0 • Hormone therapy (Progesterone or Letrozole) unable to answer • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) <=5 • Durvalumab with Platinum-based Chemotherapy 0 • Pembrolizumab with Platinum-based Chemotherapy <=5 • Any other SACT 0 | |
| Question Number 5: Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 5: No, the Trust is not currently participating in any clinical trials for the treatment of endometrial cancer. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
